Provided by Tiger Trade Technology Pte. Ltd.

Femasys Inc

0.5681
+0.01803.27%
Post-market: 0.56840.0003+0.05%19:52 EDT
Volume:313.09K
Turnover:178.89K
Market Cap:33.80M
PE:-0.82
High:0.5893
Open:0.5567
Low:0.5537
Close:0.5501
52wk High:1.76
52wk Low:0.3067
Shares:59.50M
Float Shares:49.76M
Volume Ratio:0.56
T/O Rate:0.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6900
EPS(LYR):-0.8450
ROE:-376.23%
ROA:-69.37%
PB:7.42
PE(LYR):-0.67

Loading ...

Femasys Partners with Refuah Health Center to Expand Access to FemaSeed

Reuters
·
Jan 13

Femasys Announces Partnership With Refuah Health Center to Expand First-Line Access to Femaseed® in Community-Based Care

THOMSON REUTERS
·
Jan 13

Femasys Secures FDA Clearance for Next-Generation FemVue Controlled Device

Reuters
·
Dec 18, 2025

Femasys Secures U.S. FDA Clearance for Next-Generation Femvue Diagnostic Device

THOMSON REUTERS
·
Dec 18, 2025

PharmaCyte sells Femasys stake, sees cash position rising to $20M

TIPRANKS
·
Nov 25, 2025

Femasys Initiated at Buy by Laidlaw & Co.

Dow Jones
·
Nov 20, 2025

Femasys initiated with a Buy at Laidlaw

TIPRANKS
·
Nov 20, 2025

Femasys: Strategic Advancements and Financial Health Justify Buy Rating

TIPRANKS
·
Nov 20, 2025

Femasys Q3 sales rise, driven by FemBloc sales

Reuters
·
Nov 15, 2025

Femasys Q3 EPS $(0.10) Beats $(0.12) Estimate, Sales $729.394K Miss $1.450M Estimate

Benzinga
·
Nov 15, 2025

Femasys Inc. reports nine-month sales of $1.48 million and net loss of $14.68 million

Reuters
·
Nov 15, 2025

Femasys Inc. Q3 EPS USD -0.1

THOMSON REUTERS
·
Nov 15, 2025

Press Release: Femasys Announces Third Quarter Financial Results for 2025

Dow Jones
·
Nov 15, 2025

Femasys advances global growth with second partner order for FemBloc in Europe

TIPRANKS
·
Nov 10, 2025

Femasys Secures $500,000 Order for FemBloc Launch in France and Benelux

Reuters
·
Nov 10, 2025

Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe

GlobeNewswire
·
Nov 10, 2025

Femasys Secures $12 Million Through Private Placement

TIPRANKS
·
Nov 08, 2025

Femasys Inc. Announces Private Placement of Convertible Notes and Warrants

Reuters
·
Nov 08, 2025

Femasys Secures FDA IDE Approval to Advance Final FemBloc Trial Phase

Reuters
·
Nov 03, 2025

Femasys Inc: Agreement to Issue $12 Mln Principal Amount of Senior Secured Convertible Notes, Warrants to Purchase Shares of Common Stock for $58 Mln

THOMSON REUTERS
·
Nov 03, 2025